Hyperuricosuric calcium nephrolithiasis.
Since the findings of Yü and Gutman [1], the hyperuricosuric calcium stone former is a unique clinical entity. While an impressive number of clinical and epidemiologic studies implicate hyperuricosuria in calcium stone formation, the exact physicochemical mechanism by which uric acid affects calcium oxalate crystallization has not been proven. Allopurinol decreases stone recurrences and is the drug of choice for patients with isolated HCN.
Sorensen
Carsten M
CM
Division of Urology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Box C-319, Denver, CO 80262, USA.
Chandhoke
Paramjit S
PS
D000493:Allopurinol / Q000627:therapeutic use; D002129:Calcium Oxalate / Q000378:metabolism* / Q000652:urine; D002951:Citrates / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006073:Gout / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy / Q000378:metabolism*; D020347:Lithiasis / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D014527:Uric Acid / Q000378:metabolism* / Q000652:urine
D002951:Citrates; D006074:Gout Suppressants; D002129:Calcium Oxalate; D014527:Uric Acid; D000493:Allopurinol